Introduction
============

The genetic architecture of colorectal cancer (CRC) susceptibility encompasses a broad spectrum of risk, from rare, highly penetrant germline mutations to common low-penetrance polymorphisms, each individually conferring small risks.^[@bib1]^ Some models are consistent with a polygenic basis of cancer susceptibility; however, the majority of heritable risk remains unexplained.

Heritable factors account for \~35% of CRC risk.^[@bib2]^ The remaining inherited variation is thought to be due to low-penetrance variants.^[@bib3]^ The common disease--common variant hypothesis suggests that many common low-penetrance alleles confer very slight increased risk and work synergistically to increase overall risk.^[@bib4]^ In contrast, the common disease-rare variant model proposes alleles, which exert a higher risk but have a frequency of less than 5%. Founder effects resulting from genetic drift mean these variants are largely population-specific.^[@bib4]^

Complex pathways involving many molecules have evolved to perform DNA repair. These include base excision repair (BER), nucleotide excision repair (NER), double-strand break repair, consisting of non-homologous end joining (NHEJ) and homologous recombination repair (HRR), direct reversal repair (DRR), and mismatch repair (MMR). Thousands of random DNA mutations occur during DNA replication; however, because of these highly conserved DNA repair mechanisms, fewer than one in 1000 persist.^[@bib5]^ Given that carcinogenesis requires the acquisition of somatic mutations by susceptible cells, it follows that DNA repair mutations would increase the risk of CRC and other malignancies.^[@bib6]^ In fact, recent studies have shown that mutations in DNA repair and replication genes are present in over 58% of cancer cell lines.^[@bib7]^ However, the role of low-penetrance polymorphisms of DNA repair genes in CRC risk remains unclear.

High-penetrance germline mutations in BER and MMR result in known hereditary CRC syndromes such as *MUTYH*-associated polyposis and Lynch Syndrome, respectively.^[@bib8]^ Furthermore, mutations in BER are also linked to non-CRCs such as xeroderma pigmentosum, underlining the importance of DNA repair mutations as high-penetrance risk factors for cancer.^[@bib5]^

Knowledge of which DNA repair gene low-penetrance polymorphisms have a role in CRC will enable risk assessment and individualized treatment, allowing a more personalized approach to medicine. A better understanding of CRC carcinogenesis is therefore imperative and, consequently, a systematic review and meta-analysis investigating the association of DNA repair gene polymorphisms with CRC risk was conducted.

Methods
=======

The systematic review and meta-analysis was conducted according to the principles endorsed in the PRISMA-P statement.^[@bib9]^

Literature search
-----------------

An extensive literature search of the PubMed and Embase databases from inception was conducted. Initially the following terms were searched: "DNA Repair Polymorphism" odds ratio (OR) "DNA repair risk" AND "colorectal cancer". Within Embase "DNA Repair" AND "Colorectal Cancer" were also searched.

For each specific gene or polymorphism identified, a subsequent search was performed using the terms: "rs number" or "polymorphism (e.g., T656G)" AND "colorectal cancer" or "colorectal carcinoma" or "polymorphism" or "variant".

A further literature search was conducted using the Human Genome Epidemiology Network (HuGENet) database: "\[Gene name\]" and "colorectal neoplasia".

Eligibility criteria
--------------------

Two independent reviewers (N.A. and S.S.) assessed the search strategy results. The study titles were examined for potential relevance and the abstract was then reviewed. Subsequently, the full text was retrieved to ensure eligibility.

The bibliographies of relevant articles were inspected for further eligible studies. Previous meta-analyses studying polymorphisms of interest were also reviewed ([Figure 1](#fig1){ref-type="fig"}).

If multiple studies included the same cohort of cases or controls, the study with the largest sample size was used. In the case of any uncertainty regarding study inclusion, another investigator (K.M.) was consulted to assess eligibility ([Table 1](#tbl1){ref-type="table"}).

Data extraction
---------------

Extracted data includes: title, first author, publication year, polymorphism(s) investigated, number of cases and controls, ethnicity of subjects, country from which subjects were ascertained, number of cases and controls genotyped, genotype frequencies for cases and controls, genotype frequencies within male and female cases, and controls and genotype frequencies stratified according to colon or rectum cancer.

If the required data were unavailable within the full text or any accompanying [Supplementary Material](#sup1){ref-type="supplementary-material"} online, it was sought via correspondence with the relevant authors.

Statistical analysis
--------------------

Hardy-Weinberg equilibrium (HWE) was calculated for control groups and is defined as *p*^2^+2*pq*+*q*^2^=1, whereby *p* and *q* denote the frequencies of dominant and minor alleles, respectively, at a single gene locus. Pearson's *χ*^2^-test was used to assess any statistically significant difference between expected and observed genotype frequencies. An *χ*^2^-value greater than 3.84 (*P*\<0.05) signified deviation from HWE.

Quantitative synthesis involved calculating allele-specific pooled OR for three or more studies.

Assuming that AA is the genotype frequency of the single nucleotide polymorphism (SNP), AB the heterozygote genotype frequency and BB the wild-type (Wt) genotype frequency, the frequencies were calculated as follows:

If (A) cases and (A) controls correspond to the allele frequencies of the "at-risk" groups with and without CRC, respectively, and (B) cases and (B) controls are the allele frequencies of the unexposed groups, the following equation was used to determine the pooled ORs:

Corresponding 95% confidence intervals (CIs) were deemed statistically significant if they did not cross 1.

Heterogeneity was determined by Cochrane's Q test and the *I*^2^ statistic. If the *I*^2^ value was between 50 and 100%, the DerSimonian and Laird random effects method was used to generate pooled ORs.^[@bib10]^ If the *I*^2^ value was between 0 and 50, then the Mantel--Haenszel fixed effects method was used.^[@bib10]^

Sensitivity analysis was achieved by removing each study individually and repeating the analysis.

Publication bias was assessed using funnel plots and was quantitatively assessed using Egger's test in meta-analyses containing 10 or more studies.^[@bib11]^

Subgroup analyses were conducted for ethnicity and cancer location, provided there were at least three studies. *χ*^2^-test was used to assess a significant difference between the subgroups for ethnicity. Colon and rectum cancer cases were compared to controls because it is not possible to segregate controls into colon or rectum cancers.

Statistical analyses were performed using the Metafor package in R (Version 3.2.4).^[@bib12]^

Results
=======

The comprehensive literature search identified 61 polymorphisms in 26 different DNA repair genes with case--control studies eligible for inclusion.

Meta-analyses were conducted for 22 of these polymorphisms in 17 genes, including between 1,706 and 9,682 CRC cases per polymorphism. Study numbers ranged from 3 to 13 ([Supplementary Table 1](#sup1){ref-type="supplementary-material"} online). For two polymorphisms (*RAD18* rs272572 and *MSH2* rs2303425) the meta-analysis was constituted by two studies with three different population groups reported. Minor allele frequencies ranged from between 0.0513 and 0.4571, as gathered by the 1000 genomes project.^[@bib13]^

Five polymorphisms were identified to have a significantly increased risk of CRC: *APE1* rs1130409, *PARP1* rs11136410, *ERCC5* rs17655, *XPC* rs2228001, and *RAD18* rs373572. However, *MGMT* rs12917 had a significantly decreased risk of CRC. The remaining polymorphisms did not demonstrate a significant association in meta-analysis ([Table 2](#tbl2){ref-type="table"}).

Forest plots for polymorphisms that were meta-analyzed displayed pooled ORs with 95% CI as well as study weightings. The forest plot for the polymorphism *ERCC5* rs17655 within the NER pathway is shown in [Figure 2](#fig2){ref-type="fig"}.

Subgroup analysis
-----------------

Subgroup analysis was performed by tumor location and ethnicity. There was insufficient data for subgroup analysis by gender.

Tumor location
--------------

For *OGG1*, the polymorphism rs1052133 is associated with a significantly increased risk of rectum cancer 1.18 (1.03--1.34 95% CI) but not of colon cancer 0.93 (0.81--1.06 95% CI). No other significant associations were identified.

Ethnicity
---------

Subgroup analysis by ethnicity was performed for *OGG1* rs1052133, *XRCC1* rs25487, and *ERCC1* rs11615 ([Table 3](#tbl3){ref-type="table"}). For all three, neither European nor Chinese patients were associated with risk of CRC. There were also no significant differences between ethnicities and the 95% CI calculated for the ORs overlap between the two subgroups.

Sensitivity analysis
--------------------

Sensitivity analysis was performed for 12 polymorphisms. For both *XRCC1* rs1799782 and *XPD* rs13181, removal of the studies by Gsur *et al.*^[@bib14]^ and Sliwinski *et al.*^[@bib15]^ yielded ORs indicating significantly increased risk of CRC, although previously the result was insignificant. For *XPC* rs2228001, removal of the studies by Wu *et al.*,^[@bib16]^ Liu *et al.*,^[@bib17]^ and Aizat *et al.*^[@bib18]^ yielded nonsignificant ORs, indicating no association with CRC, although previously the result was significant. However, a difference in heterogeneity was found after removal of studies by Wu *et al.*^[@bib16]^ and Liu *et al.*^[@bib17]^ ([Table 4](#tbl4){ref-type="table"}). Removal of all other studies did not change pooled OR significance for any polymorphism.

Publication bias
----------------

The majority of funnel plots were symmetrical and, therefore, did not demonstrate publication bias. Exceptions include *XRCC1* rs25487 and *XRCC1* rs1799782 ([Figure 3](#fig3){ref-type="fig"}).

Despite this, Egger's test indicated no significant funnel plot asymmetry for any polymorphism, supporting the absence of publication bias ([Table 5](#tbl5){ref-type="table"}).

Meta-analysis could not be conducted for 39 polymorphisms because of insufficient numbers of reported studies ([Supplementary Table 2](#sup1){ref-type="supplementary-material"} online). Of these, a statistically significant association with CRC risk was identified for six polymorphisms in individual published reports.

Discussion
==========

This study investigated the association between low-penetrance polymorphisms in DNA repair genes and CRC. As carcinogenesis is associated with an accumulation of acquired somatic mutations, it follows that changes in DNA repair genes would lead to genomic instability and influence an individual's susceptibility to cancer.^[@bib6]^ Six polymorphisms within six genes in the BER, HRR, NER, and DRR pathways were found to be significantly associated with the risk of CRC. The importance of DNA repair genes is indicated and polymorphisms in critical genes can, therefore, indeed alter the susceptibility to CRC.

Base excision repair
--------------------

BER involves correcting everyday oxidative and alkylative modifications to bases or the sugar phosphate backbone together with most forms of spontaneous hydrolytic decay.^[@bib19]^

This study found no association between the polymorphisms rs3219489 and rs1052133 of the two DNA glycosylase genes *MUTYH* and *OGG1*, respectively, corroborating with studies by Piceli *et al.*^[@bib8]^ and Zhang *et al.*^[@bib20]^ However, as there were only three eligible studies for *MUTYH* rs3219489, sensitivity analysis was not possible. Interestingly, subgroup analysis revealed that the association between rectum cancer and *OGG1* rs1052133 was discernible. Therefore, one can conclude that there is no association between *OGG1* rs1052133 and colon cancer, but further studies with large population groups and varying ethnicities, enabling subgroup analysis, are warranted to assess risk of *MUTYH* rs3219489 with CRC and risk of *OGG1* rs1052133 with rectum cancer.

After base removal by DNA glycosylase, APE1 catalyzes an acid--base reaction to incise the phosphodiester bond of DNA.^[@bib19]^ PARP1 binds to single strand break intermediates formed by APE1 incision. This study found significant associations between *APE1* rs1130409 and *PARP1* rs1136410 with CRC risk, although Shen *et al.*^[@bib21]^ and Hua *et al.*^[@bib22]^ revealed no such associations. The discrepancy may lie in the different methodologies such as the per-allele model or the more stringent inclusion/exclusion criteria used in the present study. Allowing studies with fewer cases increases the number of included studies but may not reliably reflect the studied population. Future meta-analyses should therefore have similarly rigorous inclusion/exclusion criteria.

XRCC1 is a key effector in the final step of BER. Coupled with DNA ligase IIIα, a covalent phosphodiester bond between 3′-OH end of the upstream nucleotide and the 5′-PO~4~ is formed. This is termed "nick sealing".^[@bib19]^ Meta-analyses conducted for polymorphisms rs25487, rs25489, and rs1799782 revealed no statistically significant association with CRC. Qin *et al.*^[@bib23]^ concurred for rs25487 and Liu *et al.*^[@bib24]^ also found no association with CRC risk for all three polymorphisms. Sensitivity analysis revealed that removal of the study by Gsur *et al.*^[@bib14]^ would result in a statistically significant association with CRC for the polymorphism rs179978. Asymmetrical funnel plots for rs25487 and rs1799782 revealed possible publication bias, possibly because smaller studies showing no statistically significant effects remain unpublished. Nevertheless, Egger's test revealed no publication bias for either polymorphism. However, more studies are required before making any conclusive determination regarding the association of each polymorphism with CRC risk.

Double-strand break repair
--------------------------

There are two major conserved pathways for the repair of double-strand breaks: HRR and NHEJ. HRR involves transfer of nucleotide sequence information from the intact DNA double helix to the site of the double-strand break of the broken helix.^[@bib5]^ NHEJ involves binding of the Ku heterodimer to the double-strand break to serve as a scaffold allowing other NHEJ factors to be recruited, such as the XRCC4-DNA Ligase IV complex to ligate the ends.^[@bib25]^ Because of insufficient number of studies, meta-analyses could not be conducted on polymorphisms of NHEJ genes.

RAD51 catalyzes the strand invasion step allowing homologous pairing. Meta-analyses by Cheng *et al.*^[@bib26]^ and the present study revealed that *RAD51* rs1801320 was not associated with CRC risk. Interestingly, only one included study^[@bib27]^ suggests significant association between CRC and the polymorphism, with an OR notably lower than the other studies. Nevertheless, sensitivity analysis revealed no marked change. XRCC3 is a paralog of RAD51 and combines with RAD51C, although its mode of action as a mediator is unclear.^[@bib28]^ Meta-analyses by Namazi *et al.*,^[@bib29]^ Liu *et al.*,^[@bib24]^ and the present study found no association between *XRCC3* rs861539 and CRC risk. Contrary to larger studies, the smaller studies by Nissar *et al.*^[@bib30]^ and Jin *et al.*^[@bib31]^ showed significant association with CRC risk, indicating the importance of a large population number. Although this polymorphism may not be associated with CRC, it is vital to search for other polymorphisms of *XRCC3* and to better understand the function of this protein.

*RAD18* is integral in the orchestration of HRR and enhances polymerization of *RAD51* by transmitting DNA damage signals at sites of DNA breaks.^[@bib32]^ To our knowledge, this is the first meta-analysis of any *RAD18* polymorphism and risk of CRC. A significant association was found for *RAD18* rs373572, but given the low number of studies included, it is vital that more case--control studies are conducted to further assess its association with colorectal carcinogenesis.

Mismatch repair
---------------

MMR corrects mismatches created largely during DNA replication.^[@bib33]^ MMR increases the accuracy of DNA 20--400-fold, and so any defects raise the spontaneous mutation rate.^[@bib33]^

Meta-analyses were conducted for *MLH1* rs1799977, *MSH2* rs2303425, and *MSH6* rs1042821. Results revealed no significant association with CRC risk. Chen *at al*.^[@bib34]^ also found no association between *MLH1* rs1799977 and CRC risk but, notably, included studies that did not meet the inclusion criteria of the present study. Given the small number of eligible studies, sensitivity analysis could only be conducted on *MLH1* rs1799977, revealing no significant difference. Many studies were excluded based on the inclusion of those with hereditary syndromes or no histological confirmation of cases. It is imperative that further studies assess patients with MMR gene polymorphisms and risk of sporadic CRC in particular.

Nucleotide excision repair
--------------------------

NER has two pathways: the global genome NER sub-pathway and transcription-coupled NER. The genome NER pathway repairs lesions throughout the genome and is triggered by helix distortion, whereas transcription-coupled NER is confined to the repair of transcription blocking DNA lesions triggered by the stalling of RNA polymerase III.^[@bib35]^ In the next steps, the two sub-pathways converge and form a transcription initiation factor IIH complex. The core proteins remain the same except XPC, which is specific to genome NER.

XPC is the first factor to detect lesions and recruit other repair machinery to form a transcription initiation factor IIH complex.^[@bib35]^ Meta-analyses conducted by Wang *et al.*^[@bib36]^ and the present study for the polymorphism rs2228000 revealed no significant association with risk of CRC. Nevertheless, given the small number of eligible studies, further case--control studies must be conducted to better understand the relationship this polymorphism may have with CRC risk. Meta-analysis for the polymorphism rs2228001 revealed a significant association with CRC. This concurs with Peng *et al.*^[@bib37]^ and Liu *et al*,^[@bib38]^ although both included studies ineligible for this meta-analysis. This result should be treated cautiously as it was only just statistically significant and sensitivity analysis revealed removal of studies by Wu *et al.*,^[@bib16]^ Liu *et al.*,^[@bib17]^ or Aizat *et al.*^[@bib39]^ would leave an insignificant result showing no association with CRC risk.

Ultraviolet damage repair has been shown to be dependent on p53 action.^[@bib40]^ Nevertheless, it is not known whether p53 directly participates or whether the response is mediated through p53-regulated gene products.^[@bib40]^ Meta-analyses by Economopoulos *et al.*,^[@bib41]^ Liu *et al.*,^[@bib42]^ and this meta-analysis found no association with the polymorphism *TP53* rs1042522 and risk of CRC. However, due to insufficient data, subgroup analyses were not possible in the present study but Liu *et al.*^[@bib42]^ and Economopoulos *et al.*^[@bib41]^ concluded that race-specific effects may feature. Additional studies providing sufficient data for subgroup analyses are desirable.

Mutations in XPD prevent it from interacting with the transcription initiation factor IIH complex, hence reducing its helicase activity and increasing the chance of repair defects.^[@bib15]^ Zhang *et al.*^[@bib43]^ and the present meta-analysis revealed no significant association for both rs13181 and rs1799793 with CRC risk. However, sensitivity analysis revealed that removal of the study by Sliwinski *et al.*^[@bib15]^ would show a statistically significant result for rs13181, albeit marginally. Given that subgroup analysis was not possible for both polymorphisms and the small number of qualifying studies for rs1799793, more studies are imperative to better understand the role of *XPD* polymorphisms and risk of CRC.

Lesion excision is the point at which the reaction must be completed to avoid leaving dangerous intermediates. Structure-specific endonucleases, XPF-ERCC1 complex, and XPG (encoded by *ERCC5*) incise 5′ and 3′ from the lesion, respectively.^[@bib35]^ To our knowledge, this is the first meta-analysis conducted on a polymorphism of *ERCC1* and CRC risk. Results revealed no association between *ERCC1* rs11615 and risk of CRC. Furthermore, Zeng *et al.*^[@bib44]^ and this meta-analysis found a significant association between *ERCC5* rs17655 and CRC risk. However, a lack of sufficient data prohibited subgroup analyses. This study allows insight into the role these polymorphisms may have in CRC carcinogenesis but further research is required to conclusively determine it.

Direct reversal repair
----------------------

DRR involves removal of alkylating groups in *O*^6^-methylguanine base residues, produced by endogenous and exogenous alkylating agents. Therefore, MGMT has an important role in preventing carcinogenesis.^[@bib45]^

Meta-analyses by Chen *et al.*,^[@bib46]^ Lu *et al.*,^[@bib47]^ and the present study found no association for the polymorphisms *MGMT* rs12917 and rs2308321 with CRC risk. Subgroup analyses were not possible due to insufficient data. Given the small number of eligible studies, more case--control studies are warranted to clarify whether these two polymorphisms have a role in the development of CRC.

Limitations
-----------

Many polymorphisms could not be investigated due to a low number of eligible studies or due to insufficient population size. Patients should be advised about the importance and possible beneficial effects of enrollment in such research studies. Increased patient numbers would allow greater reliability and statistical power when detecting an association.

Data such as genotype frequencies or patient demographics were often missing from studies, limiting subgroup analyses to tumor location and European/Chinese ethnicities. It would benefit the scientific community if publications would provide these data in the form of [Supplementary Tables](#sup1){ref-type="supplementary-material"} online or facilitate requests to allow extensive and complete analyses. In particular, study designs should allow investigation of whether variants differ significantly by other ethnicities and by gender.

The bulk of published literature reviewed in this meta-analysis subdivides tumors by rectum/colon location rather than by right and left sides. However, the differentiation of CRC by left and right sides is more biologically and clinically meaningful, and future study design should follow the right/left-sided paradigm. An example of this is the prevalence of microsatellite-unstable tumors on the right side of the colon.

Cases were often not histologically confirmed and therefore not included. It is vital histology is performed to ensure correct diagnoses of cases and to avoid misinterpretation of results.

The role of DNA repair gene polymorphisms and colorectal carcinogenesis
-----------------------------------------------------------------------

This comprehensive analysis demonstrates the association of DNA repair gene polymorphisms with CRC risk. However, given that the ORs calculated are very small and often only just significant, it is conceivable that the polymorphisms act synergistically to affect risk of CRC. It was not possible to assess this in the present study, and should be investigated in future larger studies.

Sixty-one polymorphisms were investigated and twenty-one were meta-analyzed. However, these polymorphisms account for a small proportion of all DNA repair gene polymorphisms, and it is likely there are many more, which are associated with risk of CRC, which requires a systematic whole-genomic approach.

This study synthesizes current published information regarding which DNA repair gene polymorphisms are associated with risk of CRC. This knowledge will allow physicians to risk assess patients more comprehensively in the future, enabling them to diagnose earlier and provide advice accordingly. It enhances our understanding of the pathophysiology of CRC carcinogenesis and can allow the production of better treatments, which may be tailored to meet the needs of each individual patient.

Although the functional role of these pathways is clearly very important in carcinogenesis, the functional role of the polymorphisms identified is less clear, and such studies, although required, are technically difficult, and need to be robust in their design. DNA repair and genome integrity SNPs are remarkable by their absence from the list of common CRC predisposition variants---no known DNA repair gene is tagged by the known predisposition SNPs for CRC in GWAS. One possible explanation is that these highly conserved pathways are so important to the cell that any alleles with more than very small functional effects are strongly selected against. Nevertheless, common DNA repair alleles with very small effects on cancer risk may still exist, yet their effects may be too small (with OR\<1.4 per allele) to be detected individually even in the large sample size required for GWAS.

Conclusion
==========

This study identified a significant association between six DNA repair gene polymorphisms and risk of CRC. This knowledge allows a better understanding of global risk and the role of DNA repair genes in colorectal carcinogenesis. The results indicate that further studies are warranted and should focus on assessing whole-genomic polymorphism risk and the synergistic effects of this variation on CRC risk. This study will enable inclusion of these DNA repair gene polymorphisms in future CRC risk assessments, and may ultimately contribute to global CRC risk assessment and personalized care pathways pending further data.

[Supplementary Information](#sup1){ref-type="supplementary-material"} accompanies this paper on the Clinical and Translational Gastroenterology website (http://www.nature.com/ctg)
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![Flowchart showing selection process of studies for the polymorphism rs1799782 within gene *XRCC1.*](ctg201735f1){#fig1}

![Forest plot of *ERCC5* rs17655 within the NER pathway. The author, OR, 95% CI and study weightings are shown. Analysis using the Mantel--Haenszel fixed effects model shows *ERCC5* rs17655 is associated with a significantly increased risk of CRC. CI, confidence interval; CRC, colorectal cancer; NER, nucleotide excision repair; OR, odds ratio.](ctg201735f2){#fig2}

![Funnel plot for *XRCC1*, rs25487. Studies represented as dots are plotted against log OR on the *x* axis and standard error on the *y* axis. Unequal number of studies on each side of the vertical line indicates publication bias is present. Nevertheless, Egger's test reveals no significant funnel plot asymmetry ([Table 5](#tbl5){ref-type="table"}). OR, odds ratio.](ctg201735f3){#fig3}

###### Table indicating the eligibility criteria used to select relevant studies

  **Inclusion criteria**                                                              **Exclusion criteria**
  ----------------------------------------------------------------------------------- ---------------------------------------------------------------------------------------
  Investigated the association between a polymorphism of DNA repair genes in CRC      Control population is not in Hardy--Weinburg equilibrium
  Case--control study utilizing at least 100 cases and 100 controls                   Case only studies or review articles
  Sufficient data available for analyses to be conducted                              Insufficient information within the article for inclusion/exclusion to be established
  Histologically confirmed cases of colon or rectal cancer at the time of the study   Study contained subjects with known hereditary syndromes, e.g., FAP or HNPCC
  Unselected population                                                               Controls with known adenomas or polyps
  Full articles published in English within a peer-reviewed journal                   Insufficient information within the article for inclusion/exclusion to be established

CRC, colorectal cancer; FAP, familial adenomatous polyposis; HNPCC, hereditary non-polyposis colorectal cancer.

###### Polymorphisms included within the meta-analysis and their association with CRC risk

  **Pathway**                       **Gene**      **rs number**   **Number of studies**   **Cases/controls**   **Wt allele**   **Minor allele**   **MAF**      **Pooled odds ratio**   **95% CI**       ***I***^**2**^
  --------------------------------- ------------- --------------- ----------------------- -------------------- --------------- ------------------ ------------ ----------------------- ---------------- ----------------
  Base excision repair              ***APE1***    **rs1130409**   **5**                   **4,606/5,000**      **G**           **G**              **0.3756**   **1.15**                **1.06--1.24**   **36.38**
                                    *MUTYH*       rs3219489       3                       5,230/2,756          G               G                  0.3135       1.14                    0.82--1.58       88.23
                                    *OGG1*        rs1052133       13                      9,682/1,2938         C               G                  0.3021       1.05                    0.98--1.11       0.00
                                    ***PARP1***   **rs1136410**   **3**                   **2,132/4,320**      **T**           **G**              **0.1969**   **1.16**                **1.04--1.30**   **15.01**
                                    *XRCC1*       rs1799782       11                      6,190/10,454         C               A                  0.1238       1.30                    0.96--1.75       86.98
                                                  rs25487         13                      7,981/12,226         G               T                  0.2604       1.08                    0.92--1.26       80.55
                                                  rs25489         3                       2,402/3,000          G               T                  0.0671       1.03                    0.83--1.27       0.00
  Homologous recombination repair   ***RAD18***   **rs373572**    **2**                   **2,074/2,298**      **A**           **C**              **0.3524**   **1.32**                **1.16--1.49**   **0.00**
                                    *RAD51*       rs1801320       5                       1,706/1,240          G               C                  0.1432       0.83                    0.50--1.38       85.96
                                    *XRCC3*       rs861539        8                       3,850/4,566          C               A                  0.2169       1.15                    0.85--1.55       82.90
  Mismatch repair                   *MLH1*        rs1799977       4                       8,252/8,802          A               G                  0.1296       1.15                    0.96--1.37       82.88
                                    *MSH2*        rs2303425       2                       4,598/5,602          T               C                  0.1008       1.06                    0.94--1.19       0.00
                                    *MSH6*        rs1042821       3                       6,952/8,174          C               A                  0.2009       0.98                    0.80--1.20       80.04
  Nucleotide excision repair        *ERCC1*       rs11615         4                       1,890/1,650          C               A                  0.3311       1.03                    0.90--1.18       11.22
                                    ***ERCC5***   **rs17655**     **6**                   **7,912/8,772**      **C**           **C**              **0.3614**   **1.12**                **1.06--1.20**   **0.04**
                                    *TP53*        rs1042522       12                      8,164/10,176         C               G                  0.4571       1.18                    0.97--1.45       89.23
                                    ***XPC***     rs2228000       3                       3,680/5,212          C               A                  0.2330       1.06                    0.85--1.32       80.80
                                                  **rs2228001**   **7**                   **6,584/8,930**      **A**           **G**              **0.3153**   **1.08**                **1.01--1.15**   **49.46**
                                    *XPD*         rs13181         10                      4,932/6,210          G               G                  0.2366       1.21                    0.95--1.54       85.46
                                                  rs1799793       3                       1,520/2,244          G               T                  0.1954       1.13                    0.87--1.45       62.01
  Direct reversal repair            ***MGMT***    **rs12917**     **3**                   **1,528/3,332**      **C**           **T**              **0.1484**   **0.81**                **0.68--0.98**   **0.00**
                                                  rs2308321       3                       1,664/7,016          A               G                  0.0513       0.99                    0.82--1.19       0.00

CI, confidence interval; CRC, colorectal cancer; MAF, minor allele frequency; Wt, wild type.

Significant results are in bold.

###### Subgroup analysis by ethnicity for *OGG1* rs1052133, *XRCC1* rs25489, and *ERCC1* rs11615

  **Pathway**   **Gene**   **rs number**   **Wt allele**   **European per allele**   **Chinese per allele**   ***P*** **value**                
  ------------- ---------- --------------- --------------- ------------------------- ------------------------ ------------------- ------------ ------
  BER           *OGG1*     rs1052133       C               1.11                      1.00--1.23               1.03                0.93--1.14   0.32
                *XRCC1*    rs25489         G               1.04                      0.94--1.15               0.92                0.82--1.02   0.10
  NER           *ERCC1*    rs11615         C               1.11                      0.96--1.30               1.13                0.97--1.32   0.90

BER, base excision repair; CI, confidence interval; NER, nucleotide excision repair; OR, odds ratio; Wt, wild type.

European patients were compared with controls. Chinese patients were compared with controls. A *χ*^2^-test to detect subgroup difference found nonsignificant *P* values.

###### Polymorphisms for which sensitivity analysis revealed significantly different pooled ORs

  **Pathway**   **Gene**   **rs number**   **Wt allele**   **Original**   **Removed study**   **After removal of study**                                                              
  ------------- ---------- --------------- --------------- -------------- ------------------- ---------------------------- ------------------------------ ---------- ---------------- -------
  BER           *XRCC1*    rs1799782       C               1.30           0.96--1.75          86.98                        Gsur *et al.*^[@bib14]^        **1.38**   **1.02--1.85**   86.27
  NER           *XPC*      rs2228001       A               **1.08**       **1.01--1.15**      49.46                        Wu *et al.*^[@bib16]^          1.07       0.96--1.19       50.14
                                                                                                                           Liu *et al.*^[@bib17]^         1.09       0.96--1.23       56.50
                                                                                                                           Aizat *et al.*^[@bib18]^       1.06       0.99--1.13       40.66
                *XPD*      rs13181         G               1.21           0.95--1.54          85.46                        Sliwinski *et al.*^[@bib15]^   **1.28**   **1.01--1.62**   83.15

BER, base excision repair; CI, confidence interval; NER, nucleotide excision repair; OR, odds ratio.

Significant ORs and 95% CI are in bold.

###### Egger's test for funnel plot asymmetry

  **Pathway**   **Gene**   **rs number**   **Egger's *t*-value**   ***P*** **value**
  ------------- ---------- --------------- ----------------------- -------------------
  BER           *OGG1*     rs1052133       −0.2892                 0.778
                *XRCC1*    rs25487         0.9108                  0.3819
                           rs1799782       0.7366                  0.4801
  NER           *TP53*     rs104522        0.6763                  0.5771
                *XPD*      rs13181         0.2142                  0.8358
